DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer

Clinical trial NCT05334810 · UNKNOWN

Trial details

NCT number: NCT05334810
Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

HER2-positive Breast Cancer

Start date: 2022-05-01
Primary completion: 2023-12-31
Enrollment: 191

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.